Semaglutide hits liver cells

Semaglutide appears to help the liver through a direct cellular pathway, not just by making people lose weight. (cell.com) The new study, published April 15 in *Cell Metabolism*, traced that effect to liver sinusoidal endothelial cells, or LSECs, which line the liver’s tiny blood vessels and help control what passes between blood and tissue. Researchers at Sinai Health and the University of Toronto said those cells carry the receptor semaglutide uses. (cell.com) (utoronto.ca) In mouse models of metabolic dysfunction-associated steatohepatitis, or MASH, semaglutide still improved liver inflammation and scarring even when the brain pathway tied to appetite and weight loss was removed. Mice that lacked the receptor in those liver endothelial cells did not get liver improvement, even after losing 20% of body weight. (ddw-online.com) Fatty liver disease starts with excess fat in the liver; MASH is the more dangerous form, where inflammation and scar tissue build up and can progress to cirrhosis or liver failure. Semaglutide is already used for type 2 diabetes and obesity, and researchers have been trying to explain why liver markers sometimes improved more than weight loss alone would predict. (utoronto.ca) (health.harvard.edu) That question matters because semaglutide already has human trial data in liver disease. In a phase 3 trial reported in *The New England Journal of Medicine* in April 2025, about 63% of patients on semaglutide had resolution of MASH without worsening scarring, versus about 34% on placebo, and about 37% showed less fibrosis versus nearly 23% on placebo. (vcuhealth.org) (health.harvard.edu) Doctors are also talking about the drug as an add-on, not a replacement, for diet, exercise, and weight control. In Malaga, Spain, hepatologist Dr Andrade told *SUR in English* that semaglutide has shown efficacy in improving fatty liver as clinicians there see the condition in an estimated 30% to 40% of the local population. (news365.es) The backdrop is a fast-growing disease burden. A Lancet analysis published in April 2026 estimated metabolic dysfunction-associated steatotic liver disease affected about 1.3 billion people in 2023 and could reach roughly 1.8 billion by 2050. (thelancet.com) The new paper does not mean semaglutide becomes a stand-alone liver cure, and the direct-cell finding came from experimental models rather than a new randomized human trial. But it gives researchers a clearer map of why a diabetes and obesity drug is showing up in liver clinics too. (cell.com) (ddw-online.com)